Genmab — December 2017
-
solsen - kan man spørge, om Novod har splittet 2018 dara-target yderligere op?
-
evt opdeling i linie / geografi
-
tusind tak
-
han regner med en rigtig god stigning i ROW
-
hvis de 2.6 holder fra Novod, så forstummer alt snak om slow growth ihvertfald
-
As far as we also understand, the most recent weekly IMS numbers furthermore indicate (when accumulated) that November Darzalex sales is going to be a new all time high; hence just to illustrate that Darzalex remains on track for the high-end of the guided range for 2017 (our view).
-
jeg har lige plottet Novods US tal ind i omsætningsregnearket. De kunne tyde på at han regner med en (dagsjusteret) vækst på 5% frem til Q4, og så et ordentligt ryk derfra baseret på label expansion
-
Det ser ikke helt skævt ud med Novods US tal. RoW har jeg lidt sværere at regne med pga Japan og Alcyone
-
yep det sagde JvdW
-
US skattereformen er nu gået igennem repræsentanternes hus
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind